NILAI, 7th May 2015 – Steinbeis Malaysia Foundation, today launched another eight transfer centres at Inno Biologics Sdn Bhd in Nilai, as part of its on-going effort to push for knowledge and technology transfer from academia and research institutions to industry.
With this new addition, Steinbeis Malaysia Foundation currently has 66 Steinbeis Transfer Centre Networks across the nation primarily in Universiti Teknologi Malaysia (UTM), Universiti Putra Malaysia (UPM), Universiti Malaya (UM), Universiti Sains Malaysia (USM), UCSI University as well as an Industrial Mathematical Alliance Transfer Centre – collaboration between Universiti Kebangsaan Malaysia (UKM) and Universiti Tenaga Nasional (UNITEN).
The eight STCNs were officiated by Inno Biologics’ CEO Datuk Dr. Ahmed Tasir Lope Pihie, also present were Deputy Minister of Science, Technology and Innovation (MOSTI) Datuk Dr Abu Bakar Mohamad Diah and Agensi Inovasi Malaysia’s (AIM) Chief Executive Officer Mark Rozario.
In essence, the STCN is a platform that facilitates collaborations between universities as well as research institutions with industry participants, said Rozario, who added that these collaborations create pathways that promote the sharing of expertise and know-how.
These new STCNs will be focusing on Contract Manufacturing, Quality Control, Protein Science, Facility Engineering, Quality Assurance, Process Science, Stemcell and Bio Product Registration & Certification, he added.
According to Datuk Dr. Ahmed Tasir Lope Pihie, Inno Bio has a fully equipped facility and a team of experienced scientists and engineers in the field of biopharmaceutical and biomanufacturing. This collaboration creates a platform, which focuses on promoting co-operation between industry, researchers and academia. It is time for us to recognize these talents to further boost the growth of the industry.
“More and more universities and research institutions have expressed their interest to collaborate with Steinbeis Malaysia Foundation. With today’s STCN launch, the list has grown to 66 STCNs and is still expanding. This highlights the massive demand and opportunities available from the industry,” said Rozario.
The STCNs are not only repositories of solutions, technologies and innovations but also subject matter experts – providing a whole spectrum of competitive technologies and pertinent business insights, for those looking for business and industry solutions or innovations.
At today’s event, Steinbeis Malaysia Foundation also entered into agreements with Inno Biologics and USM; as well as with Inno Biologics and Tenaga Jati Bumi. These agreements were established to further explore research findings pertaining to bioprocessing technology and protein therapeutics respectively.
“With today’s agreements, we are unlocking knowledge and expertise owned by Inno Biologics, so that it could be accessible to industry participants and other parties. With their sound research capacity and experience, they could play a significant role together with Steinbeis Malaysia Foundation to bridge the gap between industry-experts,” said Rozario.
He said that leveraging on the wealth of innovations, know-how and solutions within the domains of universities has helped Baden-Württemberg the birthplace of Steinbeis Foundation become among the more prosperous regions in Europe despite having relatively few natural resources compared to other regions in Germany.
This German SME hub is also home to well known enterprises including Daimler AG, Porsche, Robert Bosch GmbH, Carl Zeiss AG and SAP AG.
To encourage SMEs to use its platforms for solutions, Steinbeis Malaysia Foundation has recently introduced the Steinbeis Innovation Vouchers (STIV), a matching innovation grant, which funds technical or non-technical research projects. The STIV grant funds up to a maximum of RM20,000 for each project.
Steinbeis Malaysia Foundation launched in August last year is a non-profit initiative of AIM that provides an industry-focused platform to stimulate industry-academia collaboration from a market-driven perspective.
It is based on Steinbeis Foundation of Germany’s proven method of collaboration between academia and SMEs. There are approximately 50 countries worldwide that have adopted and are using the Steinbeis model. Among them are the United States of America, Japan and South Korea. Malaysia is the only country in South East Asia that has established a legal entity of Steinbeis in the form of a foundation.
About Steinbeis Malaysia Foundation
Steinbeis Malaysia Foundation is a non-profit organisation established through an initiative of Agensi Inovasi Malaysia (AIM). The Steinbeis Malaysia Foundation adopts a German method of collaboration between Industry and Academia as well as subject matter experts. The aim of the collaboration is to outsource innovation for industries, hence increasing productivity for the companies. The Steinbeis headquarters is located in Stuttgart, Germany.
For inquiries please contact: Dr Abdul Reezal Abdul Latif @ 019 675 0051 firstname.lastname@example.org
About Agensi Inovasi Malaysia
Agensi Inovasi Malaysia (AIM), a statutory body established by the Government through an Act of Parliament, was created to jump start wealth creation through knowledge, technology and innovation and stimulate and develop the innovation eco-system in Malaysia towards achieving Vision 2020.
AIM’s main objectives are to:
- Generate additional revenue to contribute to Malaysia’s GDP;
- Provide additional jobs for the Malaysian workforce;
- Inspire and produce a new generation of innovative entrepreneurs;
- Facilitate the evolution of Malaysian companies into major global players.
About Inno Bio Ventures Sdn. Bhd.
Inno Bio Ventures Sdn. Bhd. is a company incorporated under the Ministry of Finance, was established in 2002 and closely affiliated with the Ministry of Science, Technology and Innovation (MOSTI). The establisment of its subsidiaries, such as Inno Biologics is a boost to the development of the biotechnology industry that meets the government inspiration to make biotechnology as one of the main contributors to the economic growth and Gross Domestic Product (GDP).
It is in line with the National Biotechnology Policy launched in 2005, which among other things, emphasizes the development of healthcare biotechnology, industrial biotechnology development, research and development and technology acquisition and development of human capital.
For more information, visit www.innovation.my.
Download Link: Press Release-STMY-INNO BIO-7may2015